In vitro partition of irinotecan (CPT-11) in human volunteer blood: The influence of concentration, gender and smoking

Anti-Cancer Drugs

Volumn 16, Issue 8, 2005, Pages 893-895

  Dumez, Herlinde ^a   Guetens, Gunther ^a   De Boeck, Gert ^a   Highley, Martin S ^a   De Bruijn, Ernst A ^a   Van Oosterom, Allan T ^a   Maes, Robert A A ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Irinotecan; Partition; Red blood cell; Smoking

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN; PLASMA PROTEIN;

ARTICLE; BLOOD COMPONENT; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ERYTHROCYTE LEVEL; DRUG PROTEIN BINDING; DRUG UPTAKE; FEMALE; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SEX DIFFERENCE; SMOKING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA TOPOISOMERASES, TYPE I; ERYTHROCYTES; FEMALE; HUMANS; MALE; SEX DISTRIBUTION; SMOKING; SPECTROMETRY, FLUORESCENCE;

EID: 24044431921     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000175584.86198.ac     Document Type: Article

References (14)

1. Dumez H, Reinhart WH, Guetens G, de Bruijn EA. Human red blood cells: rheological aspects, uptake and release of cytotoxic drugs. Crit Rev Clin Lab Sci 2004; 41:159-188.
2. Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 1995; 6:141-151.
3. Loos WJ, Verweij J, Gelderblom HJ, de Jonge MJ, Brouwer E, Dallaire BK, et al. Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20-(S)-camptothecin in humans. Anticancer Drugs 1999; 10:705-710.
4. Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997; 33:245-59.
5. Kurata D, Wilkinson GD. Erythrocyte uptake and plasma binding of diphenylhydantoin. Clin Pharmacol Ther 1974; 16:355-362.
6. Hinderling PH. Kinetics of partitioning and binding of digoxin and its analogues in the subcompartments of blood. J Pharm Sci 1984; 73:1042-1053.
7. Dumez H, Awada A, Piccart M, Assadourian S, Semiond D, Guetens G, et al. A phase I, dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for five days every three weeks in patients with advanced solid tumors. Ann Oncol 2005; in press.
8. Soepenberg O, Dumez H, Verweij J, de Jong FA, de Jong MJA, Thomas J, et al. Phase I, pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semi-solid matrix capsules in patients with solid tumors. Clin Cancer Res 2005; in press.
9. Driessen O, Highley MS, Harper PG, Maes RA, de Bruijn EA. Description of an instrument for separation of red cells from plasma and measurement of red cell volume. Clin Biochem 1994; 27:195-196.
10. de Jong FA, Mathijssen RH, de Bruijn P, Loos WJ, Verweij J, Sparreboom A, et al. Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection. J Chromatogr B 2003; 795:383-388.
11. Hinderling PH. Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev 1997; 49:279-295.
12. Dumez H, Guetens G, De Boeck G, Highley MS, de Bruijn EA, van Oosterom AT, et al. In vitro partition of docetaxel and gemcitabine in human volunteer blood; the influence of concentration and gender. Anticancer Drugs 2005; 16:885-891.
13. Sabbioni G, Jones CR. Biomonitoring of arylamines and nitroarenes. Biomarkers 2002; 7:347-421.
14. Yu MC, Skipper PL, Tannenbaum SR, Chan KK, Ross RK. Arylamine exposures and bladder cancer risk. Mutat Res 2002; 506:21-28.